Most questions about citicoline and seizures come from one of two places: someone with epilepsy wondering whether a nootropic is safe to add, or someone who has read that citicoline is neuroprotective and assumed that protection extends to seizure-related brain injury. The animal literature answers both questions less comfortably than either group expects. It contains a finding in citicoline’s favor and a finding directly against it, in different models, and the two have never been reconciled in humans because no human epilepsy trial exists.
Nothing here constitutes medical advice. Citicoline has not been approved by the FDA to diagnose, treat, cure, or prevent epilepsy or any other condition. Epilepsy is a serious neurological condition, seizure medications have narrow therapeutic windows, and adding or changing anything is a decision for a neurologist.
Key Takeaways
- No published human trial has tested citicoline in epilepsy. Everything below is rodent data [1][2][3][4].
- In a chemically induced acute seizure model, citicoline at 100 and 150 mg/kg significantly delayed seizure onset, which is an anticonvulsant signal [3].
- In a temporal lobe epilepsy model, citicoline given after seizures increased hippocampal neuronal death, microglial activation, and blood-brain barrier leakage compared with vehicle [1].
- That harmful result did not reproduce in a third model, where citicoline was simply neutral [1].
- A review of this work concluded the direction of effect depends on timing relative to the seizure [2].
- The same study that found an anticonvulsant effect also found citicoline reduced locomotion and shortened time to sleep, meaning sedation is a plausible part of the picture [3].
The Result That Favors Citicoline
A 2016 study in European Journal of Pharmacology from Ferdowsi University of Mashhad tested citicoline in the pentylenetetrazole seizure model, a standard acute chemical convulsant paradigm. Rats received a single intraperitoneal dose of 50, 100, or 150 mg/kg [3].
At 100 and 150 mg/kg, citicoline significantly delayed the latent period, meaning seizures took longer to begin than in controls [3]. The 50 mg/kg dose did not reach significance. On its own that is a clean anticonvulsant signal, and it is the finding usually cited when citicoline is described as seizure-friendly.
The same experiment measured other things, and they complicate the reading. The 100 and 150 mg/kg doses significantly decreased total locomotion, increased both the percentage of entries into and time spent in the open arms of an elevated plus maze, and reduced latency to sleep in a pentobarbital sleep test [3]. The authors described the compound as having anticonvulsant activity and a sedative effect.
Sedation and anticonvulsant activity are hard to separate in these models. A sedated animal is less motorically active and can take longer to display an observable convulsion. That does not make the finding meaningless, but it does mean “delayed seizure onset” and “genuinely raised the seizure threshold” are not the same claim, and this design cannot distinguish them.
The Combination Result
A separate 2016 study in Bulletin of Experimental Biology and Medicine, from the Research Institute of General Pathology and Pathophysiology in Moscow, used the same pentylenetetrazole model to test citicoline alongside valproate, one of the most widely used antiepileptic drugs. Given together at minimum effective doses, 70 mg/kg citicoline and 300 mg/kg valproate, the combination potentiated the anticonvulsant properties of both agents [4].
Potentiation is a double-edged observation. Read optimistically, it hints at a possible adjunct role. Read cautiously, it says citicoline can amplify the effect of an antiepileptic drug in an animal, which is exactly the kind of interaction that matters for someone whose valproate dose has been carefully titrated. The study was a short acute-convulsion experiment in rats, not a chronic dosing study, and it is not a basis for combining anything in a person.
The Result That Goes the Other Way
The most important paper here is a 2015 study in Brain Research from Hallym University in Korea, because it tested the assumption most people bring to this topic: that a neuroprotective compound should protect the brain from seizure damage.
The researchers induced temporal lobe epilepsy in adult male rats with pilocarpine, then gave citicoline at 100 or 300 mg/kg intraperitoneally two hours after seizure onset, again at 24 hours, and then daily for a week. They assessed neuronal injury and microglial activation at one week [1].
The result went the wrong way. Rather than protecting, citicoline treatment enhanced seizure-induced neuronal death and microglial activation in the hippocampus compared with vehicle-treated controls, and increased immunoglobulin leakage indicating blood-brain barrier disruption [1]. The authors flagged the finding as surprising and wrote that clinical application of citicoline after seizure needs careful consideration [1].
They then checked whether it was model-specific by repeating the design with kainate-induced seizures instead. There, citicoline did not modulate neuronal death, blood-brain barrier disruption, or microglial activation in either direction [1]. So across three paradigms the compound looks anticonvulsant, harmful, and neutral respectively. That is not a literature with a settled answer in it.
The Timing Hypothesis
A 2018 review in Current Neuropharmacology from the same Korean group tried to reconcile the contradiction, and landed on timing. Their summary is that early administration of CDP-choline immediately after seizure increased neuronal death, blood-brain barrier disruption, and microglial activation in the hippocampus, whereas a related acetylcholine precursor, alpha-GPC, started three weeks after seizure improved cognitive function, reduced neuronal death and barrier disruption, and increased neurogenesis [2].
Their proposed explanation is that acetylcholine precursors carry both epileptogenic and neuroprotective properties, and which one dominates depends on the state of the brain when the compound arrives [2]. In the acute post-seizure window, when the hippocampus is inflamed and the barrier is already compromised, adding cholinergic drive may worsen things. Later, in a recovery phase, the same class of compound may support repair.
This is a plausible mechanistic story and it is worth noting that the two arms of it involve different compounds, CDP-choline early and alpha-GPC late, so the timing comparison is not a clean within-drug one. It is a hypothesis to be tested, not an established principle.
Reading These Doses Honestly
Every dose above is intraperitoneal in rodents, at 50 to 300 mg per kilogram. Rodents metabolize compounds faster than humans do per unit body weight, and intraperitoneal injection bypasses gut and hepatic first-pass processing that oral citicoline goes through, where it is broken down to choline and cytidine before reassembly.
Converting rodent milligrams per kilogram directly to a human dose overstates the human exposure substantially, and none of these studies was designed for that conversion. Someone taking 500 mg of oral citicoline is not receiving the systemic exposure of a rat given 300 mg/kg by injection. What the animal data provides is a direction-of-effect warning and a mechanistic question, not a dose-response curve that transfers.
What This Means in Practice
For someone with epilepsy or a seizure history, the useful summary is that citicoline’s effect on seizure activity is genuinely unresolved in animals and completely untested in humans, that one well-conducted animal study found it made post-seizure brain injury worse rather than better, and that another found it potentiated an antiepileptic drug in a way that would matter if it held in people. Two of those three findings are reasons for a neurologist to be involved before anything is added.
For someone without epilepsy taking citicoline as a nootropic, none of this describes a known risk in healthy people. Citicoline has a long tolerability record at common oral doses, and no seizure signal has emerged from the human cognitive trials. The seizure literature is about brains that are already seizing, which is a different situation.
Frequently Asked Questions
Can citicoline cause seizures?
No human study has reported citicoline causing seizures, and the human tolerability record at common oral doses does not show a seizure signal. The concern comes from rodent work in which citicoline given after chemically induced seizures worsened hippocampal neuronal death and blood-brain barrier disruption [1], which is a different scenario from a healthy person taking a capsule.
Is citicoline safe if I have epilepsy?
Nobody has tested it. There is no published human trial of citicoline in epilepsy, and the animal findings point in opposite directions depending on the model and the timing [1][2][3]. That uncertainty, plus an animal finding that citicoline potentiated valproate [4], is why this belongs in a conversation with a neurologist.
Does citicoline interact with antiseizure medication?
In rats, citicoline at 70 mg/kg combined with valproate at 300 mg/kg potentiated the anticonvulsant effect of both drugs [4]. That is a single acute animal experiment and not a documented human interaction, but it is the reason anyone on a titrated antiepileptic should ask their prescriber first.
Why did citicoline make brain damage worse in one study?
In a pilocarpine temporal lobe epilepsy model, citicoline given from two hours after seizure onset increased neuronal death, microglial activation, and barrier leakage versus vehicle [1]. A later review proposed that acetylcholine precursors have both epileptogenic and neuroprotective properties, with the acute inflamed post-seizure window favoring the harmful one [2].
Does citicoline have a sedative effect?
In rats, doses of 100 and 150 mg/kg reduced total locomotion and shortened the latency to sleep, and the study authors described a sedative effect alongside the anticonvulsant one [3]. Human users more often report the opposite, alertness, so this rodent finding has not translated in any obvious way.
References
- Kim JH, Lee DW, Choi BY, Sohn M, Lee SH, Choi HC, Song HK, Suh SW. Cytidine 5′-diphosphocholine (CDP-choline) adversely effects on pilocarpine seizure-induced hippocampal neuronal death. Brain Res (2015). PMID 25446447
- Lee M, Choi BY, Suh SW. Unexpected Effects of Acetylcholine Precursors on Pilocarpine Seizure-Induced Neuronal Death. Curr Neuropharmacol (2018). PMID 28521701
- Abdolmaleki A, Moghimi A, Ghayour MB, Rassouli MB. Evaluation of neuroprotective, anticonvulsant, sedative and anxiolytic activity of citicoline in rats. Eur J Pharmacol (2016). PMID 27475676
- Karpova MN, Kuznetsova LV, Zinkovskii KA, Klishina NV. Anticonvulsant Effects of Combined Treatment with Citicoline and Valproate on the Model of Acute Generalized Convulsions Induced by Pentylenetetrazole in Wistar Rats. Bull Exp Biol Med (2016). PMID 26902360
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice. As an Amazon Associate we earn from qualifying purchases.
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
